Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price hit a new 52-week low on Tuesday . The stock traded as low as $176.77 and last traded at $181.34, with a volume of 40071 shares trading hands. The stock had previously closed at $186.15.
Genmab A/S Stock Up 2.0 %
The stock has a market cap of $12.06 billion, a price-to-earnings ratio of 10.42 and a beta of 1.10. The company has a 50 day simple moving average of $203.42 and a 200-day simple moving average of $211.96.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
